DOXIL (LIPOSOMAL)

LOE Approaching

doxorubicin hydrochloride liposome

NDAINJECTIONINJECTABLE, LIPOSOMAL
Approved
Nov 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3

Mechanism of Action

hydrochloride. The mechanism of action of doxorubicin hydrochloride is thought to be related to its ability to bind DNA and inhibit nucleic acid synthesis. Cell structure studies have demonstrated rapid cell penetration and perinuclear chromatin binding, rapid inhibition of mitotic activity and…

Clinical Trials (3)

NCT01371227Phase 1Completed

A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma

Started Apr 2011
3 enrolled
Multiple Myeloma
NCT00903630Phase 1/2Terminated

Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Started Apr 2009
15 enrolled
Fallopian Tube CancerOvarian CancerPeritoneal Cavity Cancer
NCT00744354Phase 1Terminated

Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma

Started Oct 2008
32 enrolled
Multiple Myeloma and Plasma Cell Neoplasm